BioDelivery Sciences International Hits New 1-Year High at $14.38 (BDSI)
Shares of BioDelivery Sciences International (NASDAQ:BDSI) hit a new 52-week high during mid-day trading on Monday , Stock Ratings Network.com reports. The stock traded as high as $14.38 and last traded at $13.17, with a volume of 5,616,701 shares trading hands. The stock had previously closed at $11.99.
A number of research firms have recently commented on BDSI. Analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $18.00 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $15.50 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Finally, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average price target of $19.25.
The stock’s 50-day moving average is $10.7 and its 200-day moving average is $8.60. The company’s market cap is $622.5 million.
BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings data on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. On average, analysts predict that BioDelivery Sciences International will post $-0.65 earnings per share for the current fiscal year.
BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.